Clinical Trials on Adverse Reaction to Diagnostic Agents and Kits Nos in Canada

Total 23 results

Gregory A. Dekaban
University of Western Ontario, Canada; Ontario Institute for Cancer Research

Unknown

Tracking Peripheral Blood Mononuclear Cells With Fluorine MRI (TRACK)

Adverse Reaction to Diagnostic Agents and Kits Nos

Canada
Ottawa Hospital Research Institute
McGill University; Canadian Institutes of Health Research (CIHR)

Completed

Information Systems-enabled Outreach Program for Adverse Drug Events (ISTOP-ADE)

Adverse Drug Events

Canada
Westview Physician Collaborative

Completed

Eliminating Risk of Preventable Adverse Drug Events at the Hospital-community Interface of Care (CMR)

Adverse Drug Events

Canada
McGill University
Canadian Institutes of Health Research (CIHR)

Completed

Using Novel Canadian Resources to Improve Medication Reconciliation at Discharge

Adverse Drug Events | Medication Reconciliation

Canada
University of British Columbia

Completed

The Effect of Medication Review in High-risk Emergency Department Patients

Adverse Drug Events | Adverse Drug Reactions | Medication-related Problems

Canada
University of British Columbia
Canadian Institutes of Health Research (CIHR)

Completed

5-HT3 Antagonists (Antiemetics) and Cardiac Safety

Adverse Reaction to Other Drugs and Medicines

Canada
Salmaniya Medical Complex

Completed

Pediatric Caudal Anesthesia Block. And Pain Control (CEB)

Pain, Postoperative | Anesthesia, Caudal | Adverse Reaction to Epidural Anesthesia

Bahrain
CHU de Quebec-Universite Laval

Terminated

Efficacy of Trans-tympanic Injections of a Sodium Thiosulfate Gel to Prevent Cisplatin-induced Ototoxicity (STS001)

Head and Neck Cancer | Adverse Effect | DDP

Canada
Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Silymarin (Milk Thistle Extract) in Treating Patients With Acute Lymphoblastic Leukemia Who Are Receiving Chemotherapy

Leukemia | Drug/Agent Toxicity by Tissue/Organ

United States, Canada
Dana-Farber Cancer Institute
National Cancer Institute (NCI)

Completed

Treatment of Acute Lymphoblastic Leukemia in Children

Leukemia | Drug/Agent Toxicity by Tissue/Organ

United States, Canada
Masaryk University

Recruiting

COVID-19 Vaccines Safety Tracking (CoVaST)

Adverse Reaction to Vaccine | COVID19 Vaccine

Poland, Canada, United States, Croatia, Czechia, Estonia, Ethiopia, Germany, Ghana, Mexico, Portugal, Russian Federation, Serbia, Slovenia
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Completed

Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer

Lung Cancer | Radiation Toxicity | Oral Complications | Drug/Agent Toxicity by Tissue/Organ

United States, Canada
Wellstat Therapeutics

Completed

Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer

Pancreatic Cancer | Drug/Agent Toxicity by Tissue/Organ

United States, Canada
University Health Network, Toronto

Unknown

Does Aspirin Have a Protective Role Against Chemotherapeutically Induced Ototoxicity?

Hearing Loss | Ototoxicity

Canada
McGill University Health Centre/Research Institute...

Unknown

Transtympanic Ringer's Lactate for the Prevention of Cisplatin Ototoxicity

Hearing Loss

Canada
Sunnybrook Health Sciences Centre

Recruiting

Efficacy of Sodium Thiosulfate and Mannitol in Reducing Ototoxicity in Adult Patients Receiving Cisplatin Chemotherapy

Ototoxic Hearing Loss

Canada
Sunnybrook Health Sciences Centre
London Regional Cancer Program, Canada; Toronto Sunnybrook Regional Cancer...

Recruiting

Intratympanic N-Acetylcysteine for Prevention of Cisplatin-induced Ototoxicity.

Ototoxic Hearing Loss

Canada
IGC Pharma LLC

Recruiting

IGC-AD1 Trial on Agitation in Dementia Due to Alzheimer's (IGC-AD1-P2)

Aggression | Depression | Anxiety | Alzheimer Disease | Memory Impairment | Agitated; State, Acute Reaction to Stress | Agitation,Psychomotor | Care Giving Burden | NPS | Aggressive Outburst

United States, Canada, Puerto Rico
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors

Ovarian Cancer | Extragonadal Germ Cell Tumor | Childhood Germ Cell Tumor | Drug/Agent Toxicity by Tissue/Organ

United States, Canada, Netherlands, Puerto Rico, Switzerland, Australia
Lawson Health Research Institute
Canadian Institutes of Health Research (CIHR)

Unknown

Detecting Radiation-Induced Cardiac Toxicity After Non-Small Cell Lung Cancer Radiotherapy (RICT-LUNG)

Non-small Cell Lung Cancer | Radiation Toxicity

Canada
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer

Head and Neck Cancer | Skin Reactions Secondary to Radiation Therapy

United States, Canada
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin

Unspecified Childhood Solid Tumor, Protocol Specific | Ototoxicity

Canada, United States, Australia
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

Sarcoma | Ovarian Cancer | Brain Tumor | Ototoxicity | Neuroblastoma | Liver Cancer | Central Nervous System Tumor | Extragonadal Germ Cell Tumor | Childhood Germ Cell Tumor

Canada, United States, Australia

Clinical Trials on Adverse Reaction to Diagnostic Agents and Kits Nos in Canada

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations